Paper · 20197396

Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.

Quintela-Fandino M and 15 others. Mol Cancer Ther, 2010. Cited by 21 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. Papers, record 20197396. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20197396

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.; PubMed
Journal: Mol Cancer Ther; PubMed
Year: 2010; PubMed
Publication types: Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/20197396/; PubMed
DOI: https://doi.org/10.1158/1535-7163.mct-09-0868; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC2838726/; PubMed
The journal: https://conductscience.org/library/journal-index/101132535; PubMed
Citations, by iCite: 21; iCite
Relative citation ratio, by iCite: 0.56; iCite
Revised in PubMed: 2025-05-29; PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Quintela-Fandino M	Miguel
2	Le Tourneau C	Christophe
3	Duran I	Ignacio
4	Chen EX	Eric X
5	Wang L	Lisa
6	Tsao M	Ming
7	Bandarchi-Chamkhaleh B	Bizhan
8	Pham NA	Nhu-Ann
9	Do T	Trevor
10	MacLean M	Martha

1 to 10 of 16Source PubMed

See all 16 authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Antineoplastic Combined Chemotherapy Protocols	Major topic
Benzenesulfonates	Major topic
Biomarkers, Pharmacological	Major topic
Neoplasms	Major topic
Pyridines	Major topic
Quinazolines	Major topic
Adult
Aged
Area Under Curve
Cohort Studies
Erlotinib Hydrochloride
Female
Humans
Male
Middle Aged
Models, Biological
Niacinamide
Phenylurea Compounds
Sorafenib
Treatment Outcome

Source PubMed

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by	Source
N01 CM062203	NCI NIH HHS	United States	N01CM062203	PubMed	NIH RePORTER
N01 CM062203	NCI NIH HHS	United States	N01CM062203	PubMed	NIH RePORTER
N0I-CM-62203	NCI NIH HHS	United States		PubMed	PubMed
			P30CA062203	NIH	NIH RePORTER

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Named in the paper's record
NCT00126620	Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors	Results

Source ClinicalTrials.gov

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References50

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	17,699,864	Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.	Clin Cancer Res	2007	https://conductscience.org/library/papers/17699864	PubMed
2	15,956,649	Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.	J Natl Cancer Inst	2005	https://conductscience.org/library/papers/15956649	PubMed
3	10,525,095	Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.	J Pharmacol Exp Ther	1999	https://conductscience.org/library/papers/10525095	PubMed
4	9,354,447	Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.	Cancer Res	1997	https://conductscience.org/library/papers/9354447	PubMed
5	19,289,630	Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].	J Clin Oncol	2009	https://conductscience.org/library/papers/19289630	PubMed
6	17,913,282	Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer.	Lung Cancer	2008	https://conductscience.org/library/papers/17913282	PubMed
7	15,753,462	Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.	J Clin Oncol	2005	https://conductscience.org/library/papers/15753462	PubMed
8	16,498,671	Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells.	Cytometry B Clin Cytom	2006	https://conductscience.org/library/papers/16498671	PubMed
9	17,473,200	Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.	Clin Cancer Res	2007	https://conductscience.org/library/papers/17473200	PubMed
10	16,177,570	Biomarkers to predict response to epidermal growth factor receptor inhibitors.	Cell Cycle	2005	https://conductscience.org/library/papers/16177570	PubMed

1 to 10 of 50

See all 50 references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.

PMID	Title	Journal	Year	In Papers	Source
41,716,476	Rates of Drug-Induced Uveitis: A Review by Medication Class.	Clin Ophthalmol	2026	https://conductscience.org/library/papers/41716476	PubMed
34,002,693	PHAROH lncRNA regulates Myc translation in hepatocellular carcinoma via sequestering TIAR.	Elife	2021	https://conductscience.org/library/papers/34002693	PubMed
33,235,994	Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02.	Neurooncol Adv	2020	https://conductscience.org/library/papers/33235994	PubMed
31,093,928	Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.	Clin Pharmacokinet	2019	https://conductscience.org/library/papers/31093928	PubMed
27,930,578	Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.	Medicine (Baltimore)	2016	https://conductscience.org/library/papers/27930578	PubMed
24,423,918	S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.	Br J Cancer	2014	https://conductscience.org/library/papers/24423918	PubMed
23,412,107	In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours.	Br J Cancer	2013	https://conductscience.org/library/papers/23412107	PubMed
23,358,316	Safety and feasibility of targeted agent combinations in solid tumours.	Nat Rev Clin Oncol	2013	https://conductscience.org/library/papers/23358316	PubMed
23,041,732	Current status of multimodal & combination therapy for hepatocellular carcinoma.	Indian J Med Res	2012	https://conductscience.org/library/papers/23041732	PubMed
21,827,214	Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.	Clin Pharmacokinet	2011	https://conductscience.org/library/papers/21827214	PubMed

1 to 10 of 13

See all 13 cited by

Genes18

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
ALPP	250	PubTator's text mining	https://conductscience.org/library/genes/250	NCBI Gene
ATHS	470	PubTator's text mining	https://conductscience.org/library/genes/470	NCBI Gene
CYP3A4	1,576	PubTator's text mining	https://conductscience.org/library/genes/1576	NCBI Gene
EGFR	1,956	PubTator's text mining	https://conductscience.org/library/genes/1956	NCBI Gene
EIF2AK3	9,451	PubTator's text mining	https://conductscience.org/library/genes/9451	NCBI Gene
GPT	2,875	PubTator's text mining	https://conductscience.org/library/genes/2875	NCBI Gene
IL3	3,562	PubTator's text mining	https://conductscience.org/library/genes/3562	NCBI Gene
KDR	3,791	PubTator's text mining	https://conductscience.org/library/genes/3791	NCBI Gene
KRAS	3,845	PubTator's text mining	https://conductscience.org/library/genes/3845	NCBI Gene
LIX1	167,410	PubTator's text mining	https://conductscience.org/library/genes/167410	NCBI Gene

1 to 10 of 18

See all 18 genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

Drug	ChEMBL ID	The trials list it as	Trials	In Drugs and targets	Source
SORAFENIB	CHEMBL1336	Results	1	https://conductscience.org/library/drugs/CHEMBL1336	ChEMBL
ERLOTINIB	CHEMBL553	Results	1	https://conductscience.org/library/drugs/CHEMBL553	ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20197396

GET https://conductscience.org/api/papers/v1/20197396/references?page=2

API reference For AI assistants